FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1991997816> ?p ?o ?g. }

• W1991997816 endingPage "52" @default.
• W1991997816 startingPage "44" @default.
• W1991997816 abstract "Currently, toxoplasmosis is treated with sulfadiazine and pyrimethamine. However, this treatment presents several adverse side effects; thus, there is a critical need for the development and evaluation of new drugs, which do not present the same problems of the standard therapy. Enrofloxacin is a fluoroquinolone antibiotic known to control infection against several bacteria in veterinary medicine. Recently, this drug has demonstrated protective effects against protozoan parasites such as Neospora caninum. The present study aimed to determine the effect of enrofloxacin in the control of Toxoplasma gondii infection. For this purpose, human foreskin fibroblast (HFF) cells were infected with T. gondii RH strain and treated with sulfadiazine, penicillin/streptomycin, pyrimethamine, or enrofloxacin. Following treatment, we analyzed the infection index, parasite intracellular proliferation and the number of plaques. Additionally, tissue parasitism and histological changes were investigated in the brain of Calomys callosus that were infected with T. gondii (ME49 strain) and treated with either sulfadiazine or enrofloxacin. Enrofloxacin was able to reduce the infection index, intracellular proliferation and the number of plaques in HFF cells infected by T. gondii in comparison with untreated or penicillin/streptomycin-treated ones. Enrofloxacin was more protective against T. gondii in HFF infected cells than sulfadiazine treatment (P<0.001). In addition, pyrimethamine, enrofloxacin or the associations of sulfadiazine plus pyrimethamine, enrofloxacin plus sulfadiazine or enrofloxacin plus pyrimethamine-treatments were able to reduce the plaque numbers in HFF cells infected by T. gondii when compared to medium, penicillin/streptomycin or sulfadiazine alone. In vivo experiments demonstrated that enrofloxacin diminished significantly the tissue parasitism as well as the inflammatory alterations in the brain of C. callosus infected with T. gondii when compared with untreated animals. Based on our findings, it can be concluded that enrofloxacin is a potential alternative drug for the treatment of toxoplasmosis." @default.
• W1991997816 created "2016-06-24" @default.
• W1991997816 creator A5000088928 @default.
• W1991997816 creator A5032472572 @default.
• W1991997816 creator A5033832813 @default.
• W1991997816 creator A5063815140 @default.
• W1991997816 creator A5075353585 @default.
• W1991997816 creator A5084808533 @default.
• W1991997816 date "2012-06-01" @default.
• W1991997816 modified "2023-10-18" @default.
• W1991997816 title "Enrofloxacin is able to control Toxoplasma gondii infection in both in vitro and in vivo experimental models" @default.
• W1991997816 cites W1537640495 @default.
• W1991997816 cites W1554312160 @default.
• W1991997816 cites W1751145801 @default.
• W1991997816 cites W1970126729 @default.
• W1991997816 cites W1975492167 @default.
• W1991997816 cites W1978838210 @default.
• W1991997816 cites W1982070034 @default.
• W1991997816 cites W1997948773 @default.
• W1991997816 cites W1999422888 @default.
• W1991997816 cites W2002171501 @default.
• W1991997816 cites W2005348075 @default.
• W1991997816 cites W2007749861 @default.
• W1991997816 cites W2008401110 @default.
• W1991997816 cites W2013025622 @default.
• W1991997816 cites W2023316771 @default.
• W1991997816 cites W2046391188 @default.
• W1991997816 cites W2050196678 @default.
• W1991997816 cites W2050724240 @default.
• W1991997816 cites W2053335893 @default.
• W1991997816 cites W2060629975 @default.
• W1991997816 cites W2061602246 @default.
• W1991997816 cites W2083714120 @default.
• W1991997816 cites W2086019616 @default.
• W1991997816 cites W2103037896 @default.
• W1991997816 cites W2109283875 @default.
• W1991997816 cites W2114918609 @default.
• W1991997816 cites W2129521254 @default.
• W1991997816 cites W2132834039 @default.
• W1991997816 cites W2138092988 @default.
• W1991997816 cites W2150410081 @default.
• W1991997816 cites W2159123741 @default.
• W1991997816 cites W4211140781 @default.
• W1991997816 doi "https://doi.org/10.1016/j.vetpar.2011.12.039" @default.
• W1991997816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22281151" @default.
• W1991997816 hasPublicationYear "2012" @default.
• W1991997816 type Work @default.
• W1991997816 sameAs 1991997816 @default.
• W1991997816 citedByCount "55" @default.
• W1991997816 countsByYear W19919978162012 @default.
• W1991997816 countsByYear W19919978162013 @default.
• W1991997816 countsByYear W19919978162014 @default.
• W1991997816 countsByYear W19919978162015 @default.
• W1991997816 countsByYear W19919978162016 @default.
• W1991997816 countsByYear W19919978162017 @default.
• W1991997816 countsByYear W19919978162018 @default.
• W1991997816 countsByYear W19919978162019 @default.
• W1991997816 countsByYear W19919978162020 @default.
• W1991997816 countsByYear W19919978162021 @default.
• W1991997816 countsByYear W19919978162022 @default.
• W1991997816 countsByYear W19919978162023 @default.
• W1991997816 crossrefType "journal-article" @default.
• W1991997816 hasAuthorship W1991997816A5000088928 @default.
• W1991997816 hasAuthorship W1991997816A5032472572 @default.
• W1991997816 hasAuthorship W1991997816A5033832813 @default.
• W1991997816 hasAuthorship W1991997816A5063815140 @default.
• W1991997816 hasAuthorship W1991997816A5075353585 @default.
• W1991997816 hasAuthorship W1991997816A5084808533 @default.
• W1991997816 hasConcept C150903083 @default.
• W1991997816 hasConcept C159047783 @default.
• W1991997816 hasConcept C159654299 @default.
• W1991997816 hasConcept C174802600 @default.
• W1991997816 hasConcept C203014093 @default.
• W1991997816 hasConcept C207001950 @default.
• W1991997816 hasConcept C2777035104 @default.
• W1991997816 hasConcept C2777425658 @default.
• W1991997816 hasConcept C2778048844 @default.
• W1991997816 hasConcept C2778062946 @default.
• W1991997816 hasConcept C2778128430 @default.
• W1991997816 hasConcept C2778269047 @default.
• W1991997816 hasConcept C2778512257 @default.
• W1991997816 hasConcept C2779906673 @default.
• W1991997816 hasConcept C2781154746 @default.
• W1991997816 hasConcept C501593827 @default.
• W1991997816 hasConcept C86803240 @default.
• W1991997816 hasConcept C89423630 @default.
• W1991997816 hasConcept C98274493 @default.
• W1991997816 hasConceptScore W1991997816C150903083 @default.
• W1991997816 hasConceptScore W1991997816C159047783 @default.
• W1991997816 hasConceptScore W1991997816C159654299 @default.
• W1991997816 hasConceptScore W1991997816C174802600 @default.
• W1991997816 hasConceptScore W1991997816C203014093 @default.
• W1991997816 hasConceptScore W1991997816C207001950 @default.
• W1991997816 hasConceptScore W1991997816C2777035104 @default.
• W1991997816 hasConceptScore W1991997816C2777425658 @default.
• W1991997816 hasConceptScore W1991997816C2778048844 @default.
• W1991997816 hasConceptScore W1991997816C2778062946 @default.
• W1991997816 hasConceptScore W1991997816C2778128430 @default.

• next